Navigation Links
Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
Date:7/20/2009

CAMBRIDGE, Mass., July 20 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2009. At June 30, 2009, Idenix's cash, cash equivalents and marketable securities totaled $51.7 million.

Business Highlights

  • Idenix announced today that it had successfully completed a proof-of-concept study of its lead HCV antiviral development program, IDX184, a novel once-daily liver-targeted nucleotide prodrug. This double-blind, placebo-controlled, monotherapy, dose-escalation study in HCV genotype-1-infected patients evaluated the safety and antiviral activity of IDX184. For more information on the results of this study, please see the related press release issued today by Idenix.
  • The company continued to advance its two preclinical HCV antiviral programs. Idenix is finalizing IND- or CTA-enabling preclinical studies for IDX375, a non-nucleoside polymerase inhibitor, and is preparing documentation to support initial regulatory filings. The company has synthesized the first kilogram of its lead protease inhibitor drug candidate and has initiated 28-day chronic toxicology studies in two species to support regulatory applications.
  • Finally, during the quarter, Idenix streamlined operations with the closure of its screening facility in Cagliari, Italy. This activity is now being performed at the company's laboratory in Cambridge, Massachusetts. As a result, Idenix reduced its workforce by 18 employees and incurred a restructuring charge in the quarter of $1.5 million.

"Our focus this year has been on the advancement of our HCV discov
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
2. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
3. Idenix Pharmaceuticals Reports First Quarter Financial Results
4. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
5. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
6. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
7. Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
8. Idenix to Host Conference Call Discussing Fourth Quarter 2008 Financial Results
9. Idenix Pharmaceuticals to Present at the JP Morgan 27th Annual Healthcare Conference
10. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
11. Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Draper University, ... is proud to announce that for 6 weeks ... countries will converge on the Draper University campus ... intensive, experiential program focused on entrepreneurship, building real-world ... school, currently running its sixth cohort, continues to ...
(Date:7/23/2014)... YORK , July 24, 2014 ... Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX First ... "Immune" or "the Company"), announced a collaboration to ... pemphigoid last night at an event attended by ... interested parties. Lyfebulb is a health and wellness ...
(Date:7/23/2014)... Dresden-Rossendorf (HZDR), the Vienna University of Technology and ... embedding nearly perfect semiconductor crystals into a silicon ... nanowires, very fast and multi-functional processing units can ... future. The research results will be published in ... are considered the cornerstone of future chip technology, ...
(Date:7/23/2014)... DENVER , July 23, 2014  Having the ... making is vital to accelerating business growth and achieving ... American Hospital Association (AHA) Leadership Summit, July 20-22, 2014, ... prestigious panel of hospital executives and healthcare experts discussing ... Joanne Carrocino , President & Chief Executive Officer ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 2Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 3Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 4Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin 5A crystal wedding in the nanocosmos 2MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2
... plc,(LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical ... Standards ("IFRS") for the twelve months to December ... announced its results for the same period,under US ... Shire,s strategic goal is to become the ...
... IRVINE, Calif., March 25 Masimo (Nasdaq:,MASI), ... Motion and Low,Perfusion pulse oximetry, today announced ... manufacturer and supplier of,electrocardiographs, spirometers, patient monitors ... SET technology platform as,the foundational technology of ...
... NEOG ) announced today that its net income for ... increased 34% from the previous year,s third,quarter. Net income ... share,compared to the prior year,s $1,990,000 ($0.14 per share). ... 2008 fiscal year increased 31%,to $8,923,000 from $6,822,000 in ...
Cached Biology Technology:Shire plc: IFRS Results for the Year Ending December 31, 2007 2Shire plc: IFRS Results for the Year Ending December 31, 2007 3Shire plc: IFRS Results for the Year Ending December 31, 2007 4Shire plc: IFRS Results for the Year Ending December 31, 2007 5Shire plc: IFRS Results for the Year Ending December 31, 2007 6Shire plc: IFRS Results for the Year Ending December 31, 2007 7Shire plc: IFRS Results for the Year Ending December 31, 2007 8Shire plc: IFRS Results for the Year Ending December 31, 2007 9Shire plc: IFRS Results for the Year Ending December 31, 2007 10Shire plc: IFRS Results for the Year Ending December 31, 2007 11Shire plc: IFRS Results for the Year Ending December 31, 2007 12Shire plc: IFRS Results for the Year Ending December 31, 2007 13Shire plc: IFRS Results for the Year Ending December 31, 2007 14Shire plc: IFRS Results for the Year Ending December 31, 2007 15Shire plc: IFRS Results for the Year Ending December 31, 2007 16Shire plc: IFRS Results for the Year Ending December 31, 2007 17Shire plc: IFRS Results for the Year Ending December 31, 2007 18Shire plc: IFRS Results for the Year Ending December 31, 2007 19Shire plc: IFRS Results for the Year Ending December 31, 2007 20Shire plc: IFRS Results for the Year Ending December 31, 2007 21Shire plc: IFRS Results for the Year Ending December 31, 2007 22Shire plc: IFRS Results for the Year Ending December 31, 2007 23Shire plc: IFRS Results for the Year Ending December 31, 2007 24Shire plc: IFRS Results for the Year Ending December 31, 2007 25Shire plc: IFRS Results for the Year Ending December 31, 2007 26Shire plc: IFRS Results for the Year Ending December 31, 2007 27Shire plc: IFRS Results for the Year Ending December 31, 2007 28Shire plc: IFRS Results for the Year Ending December 31, 2007 29Shire plc: IFRS Results for the Year Ending December 31, 2007 30Shire plc: IFRS Results for the Year Ending December 31, 2007 31Shire plc: IFRS Results for the Year Ending December 31, 2007 32Shire plc: IFRS Results for the Year Ending December 31, 2007 33Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 2Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 3Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide 4
(Date:7/24/2014)... . , Electric cars ... common sight on the roads of the Scandinavian country ... new vehicle registrations for the second time. This poses a ... claim only a small portion of the market. Of the ... mere 8000 are electric powered. The main factors discouraging motorists ...
(Date:7/23/2014)... 24, 2014 Pfenex Inc. (NYSE MKT: PFNX) today ... shares of its common stock at a price to the ... the underwriters a 30-day option to purchase up to 1,250,000 ... price. The shares are expected to begin trading on the ... William Blair & Company, L.L.C. and ...
(Date:7/23/2014)... (SMU) The U.S. Department of Defense recently ... a $2.6 million grant to support its goal ... fields. STEMPREP recruits bright, science-minded minority middle school ... STEMPREP project, then provides high school students with ... based at SMU,s Annette Caldwell Simmons School of ...
Breaking Biology News(10 mins):Nano-supercapacitors for electric cars 2Nano-supercapacitors for electric cars 3Pfenex Inc. Announces Pricing Of Initial Public Offering 2Department of Defense awards $2.6 million grant to SMU STEM program for minority students 2
... April 11, 2011 (BRONX, NY) Just as inhaling ... it. Two researchers at Albert Einstein College of Medicine ... grant from the National Institutes of Health to clinically develop ... before the cancer becomes malignant and spreads. The grant ...
... SEATTLE, Wash.April 12, 2011The Allen Institute for Brain ... genomically comprehensive human brain map, a previously unthinkable ... than four years of rigorous studies and documentation. ... Allen Human Brain Atlas, an online public resource ...
... material available to identify persons or find next of kin ... the kits usually employed to carry out DNA identifications do ... is not available, and that which is available is highly ... persons from these small fragments of DNA. His thesis, presented ...
Cached Biology News:NIH funds investigation of inhaled lung cancer treatment 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 3Developing a tool for identification -- even using very degraded DNA samples 2Developing a tool for identification -- even using very degraded DNA samples 3